A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) ##STR00001##
wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) ##STR00001##
wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) ##STR00001##
wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1)

##STR00001##

wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1)

##STR00001##

wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

Carbon dioxide-reversibly-protected chain extension-crosslinking agents and a preparation method and use thereof are disclosed, The carbon dioxide-reversibly-protected chain extension-crosslinking agents have chemical structures represented by Formula I, Formula II, Formula III or Formula IV, wherein, n, m and p are integers, R is either OCH.sub.2CH(CH.sub.3) or OCH.sub.2CH.sub.2, 1≤n≤20, 1≤m≤10, and 1≤p≤10. ##STR00001##

Described herein are the amphetamine-related compounds amphetamine carbamate (amphetammonium-amphetacarbamate) and amphetacarbamate, methods of making them, methods for detecting or quantitatively determining the amount of amphetacarbamate or amphetamine carbamate in a compositions, and ion chromatography columns useful in such methods.

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: ##STR00001##
wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.